Melbourne researchers have identified a previously unknown role of ‘natural killer’ (NK) immune cells, improving our understanding of how the immune system is regulated

Phase 2b study results of OPT-302, an anti-VEGF-C/-D ‘trap’ agent administered in combination with Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular

A Korean research collaboration has developed core technology for smart contact lenses that can implement augmented reality (AR)-based navigation using 3D printing.

Altos Biologics has completed patient enrolment in a global Phase 3 clinical trial of ALT-L9, an Eylea biosimilar for neovascular (wet) age-related macular degeneration